Benzinga | Nov 9, 2021 06:14PM EST

Capricor Therapeutics Q3 EPS $(0.17) Beats $(0.22) Estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 15 percent increase over losses of $(0.20) per share from the same period last year.